How should I compare two plans when their target coverage looks similar?

Confirm that they use the same prescription, anatomy, structure definitions, and dose accumulation basis. Compare target coverage and high-dose regions in all three image planes, then inspect relevant organ-at-risk metrics on a cumulative DVH. Check whether the displayed dose is absolute Gy and whether volume is shown in cubic centimeters or percent. A lower organ mean dose may conceal a small high-dose region; a favorable DVH may conceal a spatial miss or a plan that cannot be delivered reliably.

When is deformable registration useful, and what must be checked?

It can map structures or dose between image sets when anatomy has changed in shape. Inspect the image match and deformation throughout the region of interest, especially at organ boundaries, air cavities, and surgical changes. Verify the source and destination image sets, direction of the mapping, and whether dose accumulation is physically meaningful. A smooth-looking overlay alone does not establish that a mapped contour or composite dose is accurate.

What makes a contouring decision defensible?

Use the named structure and the intended image set, review axial, sagittal, and coronal views, and adjust windowing to see the relevant tissue boundary. Follow the anatomy across adjacent slices rather than drawing isolated shapes. Inspect interpolation, holes, and separated regions before committing the edit. If the boundary remains uncertain, record the location and seek the appropriate clinical review rather than extending a contour on guesswork.

CMD Medical Dosimetry Study Guide

Start with concept 1 Choose a topic

Medical dosimetry connects a prescribed treatment intent to a plan that can be calculated, delivered, checked, and understood. You need to recognize what an image or dose display actually shows, choose a calculation that fits the beam and anatomy, and trace how uncertainty affects the result. A useful plan review starts with the correct patient and prescription, then moves through geometry, target coverage, organs at risk, deliverability, and independent checks. This guide develops those decisions through self-contained cases with stated assumptions and units. It also covers the dosimetrist’s responsibility to identify discrepancies, document the reasoning, and bring clinical questions to the radiation oncologist or qualified physicist before a plan is used.

Radiation Physics

1. What changes in radioactive decay

A decay mode tells you how the nucleus changes, which in turn tells you what radiation leaves it. In alpha decay, the nucleus ejects two protons and two neutrons. Its mass number falls by four and its atomic number by two, creating a different element. In beta-minus decay, a neutron becomes a proton while an electron and an antineutrino leave the nucleus. The mass number stays fixed and the atomic number rises by one. Gamma emission releases excess nuclear energy as a photon without changing either count. A nucleus can undergo more than one step in a decay chain, so identify each transition separately. For dosimetry, the emitted particle or photon matters because its penetration, energy deposition, and shielding behavior differ. The current MDCB handbook identifies decay types within radiation physics.

Worked example: Start with a hypothetical nucleus having mass number 210 and atomic number 84. Alpha emission leaves mass number 206 and atomic number 82 because two protons and two neutrons depart. Beta-minus emission from the original nucleus instead gives 210 and 85 because one neutron becomes a proton. Gamma emission leaves 210 and 84. These outcomes describe different nuclear changes and different emitted radiation.

Watch the distinction: A common error is to subtract one from the mass number for beta-minus decay. The neutron changes identity, but the number of nucleons remains the same.

Reference: [1]

2. Activity across half-lives

Activity measures the number of nuclear transformations per second, expressed in becquerels; one MBq is one million transformations per second. Physical half-life is the time required for activity to fall to half its current value. For elapsed time t and half-life T, use A(t) = A₀(1/2)^(t/T). Divide elapsed time by half-life first, then apply that number of halvings. This describes source decay, not the dose delivered to a particular point. Dose rate also depends on emitted radiation, shielding, attenuation, source orientation, and distance. If only distance changes, activity remains the same while the radiation field at the point changes. In source planning, keep the source-strength timestamp and the treatment timestamp distinct; an otherwise correct geometry can give the wrong dose estimate if the strength is evaluated at the wrong time.

Worked example: A hypothetical source has activity 96 MBq at noon and a six-hour physical half-life. At 6 a.m. the next day, 18 hours have passed, or three half-lives. Its activity is 96 × (1/2)³ = 12 MBq. Moving it closer to a measurement point could raise the point dose rate, but its activity would still be 12 MBq at that time.

Watch the distinction: Moving a weaker source closer does not reverse radioactive decay. It changes the geometry of exposure while the source continues to have its time-dependent activity.

Reference: [1]

3. How clinical X-rays are produced

In a clinical X-ray tube or photon-producing linac head, accelerated electrons strike a target. Electrons deflected and slowed by target nuclei release bremsstrahlung photons with a range of energies. An electron that ejects an inner-shell electron can also produce characteristic X-rays when another electron fills the vacancy; the photon energy reflects the difference between shell energies. Target material, incident electron energy, and filtration influence the resulting spectrum. For an electron treatment beam, the target is removed from the beam path or bypassed according to machine design, allowing charged electrons to reach the patient. Those electrons lose energy through collisions and scatter laterally, producing a finite useful range. A photon plan instead accounts for attenuation and secondary charged particles generated in tissue. Identify what reaches the patient before selecting depth-dose assumptions.

Worked example: Consider two modes on a hypothetical treatment linac. In photon mode, electrons hit a metal target, producing bremsstrahlung and characteristic X-rays before the beam is shaped. In electron mode, the target is removed from the path and charged electrons are delivered. A shallow target might suit the latter, but its finite range and lateral scatter require an electron-specific field and dose calculation.

Watch the distinction: Electrons emerging from the accelerator do not automatically make an electron treatment beam. In photon mode, they first strike a target and the patient receives the resulting photons.

Reference: [1]

4. Photon interactions in tissue

Photon interactions depend on energy and the material crossed. In the photoelectric effect, a photon is fully absorbed and ejects a bound electron. Its probability rises strongly in higher atomic-number materials and is more prominent at lower photon energies. In Compton scattering, a photon transfers part of its energy to an electron and continues in a new direction. For many megavoltage treatment photons in soft tissue, Compton interactions dominate because their dependence tracks electron density more closely than atomic number. Pair production occurs near a nucleus when a photon has at least 1.022 MeV, the combined rest energy of an electron and positron; its probability grows at higher energies. An implant can alter attenuation and scatter and can corrupt CT numbers through artifacts. Separate the physical interaction from any imaging error before interpreting calculated dose around it.

Worked example: A megavoltage photon beam passes through soft tissue beside a dense implant. Compton scattering is the usual interaction to consider in the soft tissue. Photoelectric absorption becomes more prominent for lower-energy photons in higher atomic-number material. Pair production is impossible below 1.022 MeV photon energy, although being above that threshold alone does not make it dominant. Inspect the implant representation and nearby dose calculation.

Watch the distinction: Do not assume the highest-density object makes photoelectric absorption dominant throughout a megavoltage plan. Interaction probabilities depend on photon energy and the material at each location.

Reference: [1]

5. Photon, electron, and proton depth dose

A photon beam deposits dose after producing charged particles in tissue, then continues attenuating beyond the target; there is generally an exit-dose path. Electrons are charged particles with a finite practical range. Their energy loss can serve a shallow target while limiting deep dose, although lateral scatter and irregular surfaces can weaken edge coverage. Protons also lose energy by charged-particle interactions, with a concentrated rise in dose near the end of range called the Bragg peak. Combining proton energies can cover a target depth while reducing dose beyond it. That distal edge depends on the estimated stopping power along the entire beam path. Air cavities, density changes, and setup shifts can move it relative to an organ. Beam choice therefore starts with target depth and shape, then tests nearby anatomy, motion, and uncertainty rather than comparing one central-axis depth curve.

Worked example: A shallow target sits directly above a deep organ. An electron field may cover the target and end before much deep dose, provided its lateral edge and surface dose are adequate. Photons can cover variable depths but continue beyond the target. Protons may reduce exit dose, yet a changed tissue path could shift their distal falloff into the organ. Compare calculated coverage and uncertainty for each.

Watch the distinction: A Bragg peak does not guarantee that tissue beyond a proton target receives no dose. Range error, scattered particles, beam arrangement, and target depth coverage all matter.

Reference: [1]

6. What each treatment system delivers

Identify the delivery system by where radiation originates and how its geometry is controlled. A linac generates external photon or electron beams and can shape them with jaws and multileaf collimators. A radioactive-source unit emits photons from a contained source, so source strength and source geometry are central. An HDR afterloader temporarily drives a radioactive source through an applicator; dwell positions and times determine the steep local dose distribution. An MR-guided external beam system couples treatment delivery with magnetic resonance imaging for localization and, where supported, adaptive review. A proton machine accelerates charged particles whose range depends on the tissues crossed. Each system requires a matching planning model and verification chain. For the dosimetrist, the relevant question is which source, path, image set, and delivery parameters the approved plan actually describes.

Worked example: One prescription calls for a temporary source inside a vaginal applicator. That is HDR brachytherapy: inspect applicator reconstruction, source path, dwell positions, and source strength. Another calls for external modulated beams with daily MR images. That is MR-guided external beam treatment: inspect beam geometry, image registration, and the approved delivery parameters. The two plans cannot share the same source-position assumptions.

Watch the distinction: Daily MR imaging does not turn an external beam into brachytherapy. Imaging guides localization; the radiation source and its delivery geometry define the treatment system.

Reference: [1]

7. Projection geometry and inverse square

Projection magnification comes from similar triangles. When an object lies between a point source and detector, magnification equals source-to-detector distance divided by source-to-object distance. Define both distances along the projection axis and use matching units. A smaller source-to-object distance gives a larger projected feature. The inverse-square rule addresses a different question: for an ideal point source in free space, intensity or dose rate falls in proportion to one over distance squared. To compare positions, multiply the first rate by (first distance/second distance)². Real treatment fields may depart from this model because of finite source size, collimation, attenuation, and scatter. Do not use image magnification to infer a dose change. Establish whether the task asks about projected size or radiation intensity, then check the reference point and distance definition.

Worked example: With a source-to-detector distance of 100 cm and source-to-object distance of 80 cm, magnification is 100/80 = 1.25. A 4 cm feature projects as 4 × 1.25 = 5 cm. Separately, an ideal point-source dose rate at 120 cm is (100/120)² = 0.694 times its rate at 100 cm, assuming no attenuation or scatter changes.

Watch the distinction: Using 80/100 for magnification predicts a smaller projected object on a more distant detector. Check the triangle: the detector lies farther from the source than the object.

Reference: [1]

8. Imaging signals and CT calibration

Each imaging method answers a different planning question. Planning CT maps anatomy and provides Hounsfield units that a validated calibration table converts to density information for dose calculation. CBCT supports in-room localization, but scatter, acquisition geometry, and reconstruction can change its CT numbers. Orthogonal kV or MV images help align visible anatomy or markers, while MRI improves many soft-tissue boundaries without directly providing CT electron density. PET adds functional information whose resolution and timing limit contour precision. Surface guidance tracks visible patient surface and cannot alone establish internal target position. Match the image to its purpose: contouring, density calculation, or treatment alignment. When reviewing multimodal images, inspect registration and artifacts before using a value or boundary. The radiation therapy study guide offers related imaging context.

Worked example: A planning CT voxel is 250 HU. A hypothetical validated table assigns relative electron density 1.0 at 0 HU and 1.4 at 500 HU, with linear interpolation between them. The voxel is halfway through the interval, so its estimated density is 1.0 + 0.5 × 0.4 = 1.2. A CBCT voxel reading 250 cannot automatically use this CT-specific calibration.

Watch the distinction: A number displayed in HU does not prove that every scanner produces the same usable density estimate. Dose calculation needs calibration appropriate to that image acquisition and reconstruction.

Reference: [1]

9. Radiation quantities and attenuation

Keep radiation quantities tied to what they measure. Activity, in Bq, counts nuclear transformations per second and describes a source. Absorbed dose, in Gy, is energy deposited per unit mass; 1 Gy equals 1 J/kg. Equivalent dose, in Sv, applies a radiation weighting factor to absorbed dose in a tissue for radiation-protection purposes. Exposure is an ionization quantity defined for photons in air and is expressed in coulombs per kilogram; it is not a synonym for patient absorbed dose. A half-value layer is a material thickness that halves a specified beam intensity under stated measurement conditions. Repeated half-value layers multiply the remaining fraction by one-half each time. Beam quality, buildup, and scatter affect practical attenuation, so a narrow-beam half-value calculation should not be mistaken for a complete treatment-shielding or patient-dose calculation.

Worked example: A hypothetical photon irradiation deposits 0.020 Gy in a specified tissue. That is 20 mGy absorbed dose. With photon radiation weighting factor 1, the corresponding equivalent dose is 0.020 Sv, or 20 mSv. Separately, if a material's half-value layer is 3 cm, a 9 cm thickness contains three half-value layers and leaves (1/2)³ = 12.5% of an ideal narrow beam's initial intensity.

Watch the distinction: Twenty mGy and twenty mSv can share a numerical value in this photon example, but they name different quantities. The conversion depends on the stated weighting factor.

Reference: [1]

Localization

10. Validate the simulation data set

A plan is only as reliable as the data relationships beneath it. Start by reconciling patient and course identifiers with the prescription, then verify treatment site and laterality against the images and structure set. Check image orientation labels, acquisition date, frame of reference, slice spacing, and complete scan extent. Imported contours must map to the intended image series; a familiar structure name does not establish that association. Orientation errors can reverse anatomical interpretation, while differing slice geometry can shift or distort contours during transfer. If information conflicts, pause beam placement and dose calculation. Trace the original image and structure records, compare visible anatomy in all three planes, and obtain resolution through the clinical team. The dosimetrist can identify and document the discrepancy, but should not silently reinterpret a prescription or relabel a structure to make the data appear consistent.

Worked example: A right-sided prescription arrives with a structure set labeled left and a CT whose slice spacing differs from the planning request. Compare patient, study, series, and frame-of-reference identifiers, then inspect anatomy and contour positions. Do not copy beams or contours yet. Resolve which data set and laterality are intended with the responsible team, and verify the corrected associations before planning resumes.

Watch the distinction: A matching patient name does not establish that imported structures belong to the current CT or prescribed side. Confirm the underlying series and spatial relationships.

Reference: [1]

11. Position for repeatability

Immobilization aims to reproduce the relationship among target, organs, and treatment beams across fractions. A position that can be held briefly for simulation may fail during repeated treatment. Evaluate comfort, breathing, access, and whether supports can be indexed to the treatment couch. For head-and-neck work, mask fit, shoulder position, neck flexion, and bite or head supports can change both target location and organ separation. Reference marks and image guidance help reproduce the setup, but they cannot fully correct a different body posture or a poorly fitted device. Inspect the patient in treatment position and review simulation images for anatomy displaced by the device. If a position is unstable, adjust the setup and repeat the needed imaging before building margins or beams around it. Record the reproducible setup clearly enough for therapists to recreate it.

Worked example: A head-and-neck patient holds the intended pose for simulation but repeatedly lifts the shoulders after several minutes. The elevated shoulders could change lower-neck target and beam-path geometry. Recheck mask fit and shoulder support, use indexed devices, and establish a tolerable reference position. If the intended posture cannot be reproduced, arrange a revised setup and adequate resimulation before planning.

Watch the distinction: Adding a larger planning margin is not a complete fix for a setup the patient cannot maintain. Posture changes can alter organs and beam paths as well as target position.

Reference: [1]

12. Represent motion, not one snapshot

Respiratory motion requires a strategy matched to what the patient can reproduce. Breath hold aims to treat at a stable held position and needs verification of that position. Gating delivers only during a selected part of the breathing cycle. Tracking adjusts the beam or patient alignment to follow the target. A motion-encompassing approach covers the observed target positions, often using a four-dimensional CT to construct an internal target envelope. For each approach, inspect phase image quality and whether the measured trajectory represents treatment breathing. The internal envelope describes motion, while setup uncertainty is handled separately in planning; adding margins without identifying their purpose risks double counting. A single phase may show a sharp contour yet omit other positions. Review the target's path in three dimensions and compare the selected strategy with available localization and delivery capabilities.

Worked example: On a hypothetical four-dimensional CT, the superior edge of a small target appears at positions from 0 to 8 mm relative to a fixed reference. The observed superior-inferior span is 8 mm, so a motion envelope must include both extremes. An end-exhale contour alone excludes positions reached in other phases. Confirm that phase images and treatment breathing support this envelope before applying a separate setup allowance.

Watch the distinction: An 8 mm motion span does not automatically mean adding 8 mm in every direction. The envelope follows the observed positions, while setup uncertainty has a separate basis.

Reference: [1]

13. Check simulation completeness

Simulation images must contain the anatomy needed for contouring, beam design, and dose calculation. Check patient preparation and contrast timing where relevant, then inspect whether the field of view includes the whole body outline and every proposed entrance and exit path. Scan length must cover targets, organs requiring review, and full treatment windows with enough context for reconstruction. Truncated anatomy can make attenuation and scatter estimates unreliable; guessing an external contour supplies geometry without evidence. Image artifacts, limited contrast, or inconsistent preparation may also hide a boundary or change organ filling. Evaluate whether the data set is fit for the planned technique before optimization. If it is incomplete, identify exactly what is missing and request appropriate additional imaging or resimulation through the team. A calculation that finishes successfully does not establish that the source images were complete.

Worked example: A pelvic planning CT ends 2 cm below a proposed superior beam edge. The beam would cross anatomy absent from the scan, so the external contour and attenuation path cannot be determined there. Extend the simulation scan or obtain an adequate replacement data set, then reassess the beam and organ coverage. Extrapolating the body outline would hide the missing information.

Watch the distinction: A complete target contour does not mean the simulation is complete. Beam paths, organ review, and calculation still require anatomy beyond the target itself.

Reference: [1]

14. Register images and localize treatment

Registration aligns images for a defined clinical purpose. Rigid registration uses translation and rotation, so it works best where relevant anatomy behaves approximately as one stable unit. Deformable registration allows local shape changes, but its apparent fit must be checked against anatomy and any intended contour or dose transfer. Select a region of interest that matters to the target and organs, inspect axial, sagittal, and coronal views, and look for disagreement outside the matched region. A diagnostic MRI may improve soft-tissue identification on planning CT while differing in patient pose. Daily image-guided radiotherapy then compares treatment-day anatomy with the approved reference to position the patient; it does not repair a mistaken planning fusion. Record the registration choice and uncertainty so contours and dose interpretation retain their anatomical basis. The MDCB practice questions can help rehearse these distinctions.

Worked example: A diagnostic MRI and planning CT align well at the skull, but the neck has different flexion. Use a rigid match focused on the clinically relevant stable region and inspect all three planes. Do not assume that one transform correctly aligns the lower neck. If a neck structure needs MRI guidance, flag the mismatch for review. Daily CBCT later verifies treatment positioning against the approved plan.

Watch the distinction: A visually convincing match on one axial slice is insufficient. Registration can look accurate there while drifting in the sagittal plane or outside the chosen region.

Reference: [1]

Treatment Planning

15. Clinical pathways shape target review

Clinical anatomy helps the dosimetrist test whether a prescribed target can be represented and treated as intended. In thoracic planning, relate the primary lesion to lung lobes, pleura, mediastinal nodal stations, esophagus, heart, and spinal canal. Disease may spread locally or through regional lymphatic routes, but the physician defines which disease and elective regions belong in the clinical target. The planning review checks that those prescribed regions are visible on the simulation images, correctly labeled, and spatially consistent with the written intent. Trace a target and nearby organs through multiple slices before assessing beam access or overlap. If a named nodal region lies beyond the scan, no dose calculation can establish its coverage. Identify the missing extent and request clinical clarification or additional imaging rather than silently trimming the contour to the available data.

Worked example: A thoracic prescription includes a lung lesion and selected mediastinal nodes. On axial and sagittal review, the lesion, esophagus, and spinal canal are visible, but the superior end of one prescribed nodal region lies outside the CT. Document that the target cannot be fully contoured or evaluated on this scan and refer the missing extent for physician review and adequate imaging.

Watch the distinction: Recognizing a common route of spread does not authorize the dosimetrist to add or remove nodal regions. Use that knowledge to detect a discrepancy and obtain clinical direction.

Reference: [1]

16. From visible disease to planning volume

Planning structures encode different questions. Gross tumor volume, or GTV, represents visible or otherwise demonstrable disease. Clinical target volume, or CTV, adds tissue judged at risk for microscopic disease when prescribed. Internal target volume, or ITV, accounts for internal motion or variation in target position. Planning target volume, or PTV, adds a geometric allowance for setup and delivery uncertainty around the selected target representation. An organ at risk, or OAR, is normal tissue whose dose matters; a planning organ-at-risk volume, or PRV, adds an allowance around an OAR when its position or a steep gradient makes that useful. These are conceptual roles, not a universal sequence of fixed-distance expansions. Review how motion, setup, anatomy, and prescription interact, and confirm which structures the physician approved before optimizing coverage or organ sparing.

Worked example: A visible lesion measures 2 cm across on the reference image and moves with breathing. Label the visible disease GTV. If microscopic-risk tissue is prescribed, its clinical extent forms a CTV. Include observed motion in an ITV, then account for setup uncertainty in the planning target definition. A nearby serial organ is an OAR; a PRV can represent positional uncertainty around it. No margin size follows from the 2 cm measurement alone.

Watch the distinction: Applying the same numerical margin to every structure confuses disease extent, motion, and setup uncertainty. Each volume has a distinct purpose and requires case-specific review.

Reference: [1]

17. Site anatomy changes beam tradeoffs

Breast and regional-node plans involve several close but differently shaped structures. The breast or chest-wall target extends near skin and lung, while regional nodal targets can approach the apex and mediastinum. For left-sided treatment, heart position and any small high-dose region deserve attention alongside lung volume receiving lower or moderate dose. Beam direction and breath-hold geometry can change these relationships. Start by ensuring two plans use the same approved structures, prescription, fractionation, and anatomy. Compare target coverage and the specific organ metrics relevant to that patient, then inspect where each dose region lies on axial, sagittal, and coronal views. A single summary number can conceal a hotspot in a sensitive location or a larger low-dose bath. Present the competing effects clearly for clinical selection; the dosimetrist evaluates the tradeoff without independently setting the patient's acceptable risk.

Worked example: Two hypothetical left-breast plans have equal prescribed target coverage. Plan A lowers the heart's hottest small volume but raises the ipsilateral lung volume receiving moderate dose. Plan B does the reverse. Check that both DVHs use identical structures and dose units, locate the heart and lung regions on matched images, and present both organ metrics with target coverage for physician review.

Watch the distinction: Calling the plan with the lowest mean heart dose automatically better can miss a focal heart hotspot or a material lung tradeoff. Inspect the requested metrics and their locations.

Reference: [1]

18. Fraction size and biological effect

Fraction size changes biological effect even when total physical dose is similar. Under the linear-quadratic model, biologically effective dose is BED = nd[1 + d/(α/β)], where n is the number of fractions, d is dose per fraction in Gy, and α/β is a stated tissue-specific parameter in Gy. First calculate d from total dose and fraction count, then keep units consistent inside the ratio. BED is often labeled Gy followed by the assumed α/β value, such as Gy10. The model supports a defined comparison; it does not establish that two schedules have equal tumor control or organ safety. Overall treatment time, repair, target volume, dose distribution, and the applicability of the model at large fraction sizes also matter. Compare the relevant target and normal-tissue assumptions separately before drawing a planning conclusion.

Worked example: Assume α/β = 10 Gy for a hypothetical comparison. For 30 Gy in 10 fractions, d = 3 Gy and BED = 30[1 + 3/10] = 39 Gy10. For 24 Gy in three fractions, d = 8 Gy and BED = 24[1 + 8/10] = 43.2 Gy10. The second is higher under this assumption, but that does not make the schedules clinically interchangeable.

Watch the distinction: Comparing total Gy alone misses fraction-size effects. Conversely, treating a BED result as a complete clinical decision ignores tissue-specific assumptions and dose distribution.

Reference: [1]

19. LET and RBE in interpretation

Absorbed dose, linear energy transfer, and relative biological effectiveness describe different properties. Physical dose in Gy is energy deposited per unit mass. Linear energy transfer, or LET, describes how densely a charged particle deposits energy along its track, commonly expressed per unit path length. Relative biological effectiveness, or RBE, compares doses from two radiation types that produce the same specified biological endpoint under stated conditions. RBE depends on endpoint, tissue, dose, and radiation quality; it is not a universal multiplier inferred from LET alone. A modeled RBE-weighted dose can be calculated only after an RBE assumption is supplied: multiply physical dose by that stated factor and label the result accordingly. In plan interpretation, first identify whether displayed values are physical or biologically weighted and whether the planning system uses a fixed or varying assumption.

Worked example: Two hypothetical beams each deposit 2 Gy in a voxel, so each deposits 2 J/kg there. Their LET distributions differ, which may alter biological response. If a problem explicitly assigns RBE = 1.1 to one beam, its modeled weighted dose is 2 × 1.1 = 2.2 Gy(RBE). Without an RBE assumption and endpoint, equal physical dose cannot be converted into an asserted biological difference.

Watch the distinction: Higher LET does not supply a precise RBE by itself. Avoid converting physical Gy to weighted dose from beam type alone without the stated biological model.

Reference: [1]

20. Read cross-sectional anatomy before dose

Dose interpretation begins with anatomy. On an axial pelvic slice, identify the target and neighboring bladder, rectum, bowel, bone, and body contour, then follow each structure superiorly and inferiorly. Sagittal views reveal front-to-back relationships and organ length; coronal views show lateral extent and continuity. This multiplanar check helps distinguish a true hotspot in an organ from a dose region that merely appears adjacent on one slice. Confirm image orientation, windowing, contour boundaries, and registration before attributing dose to a structure. Then display the relevant isodose and inspect its path across slices, comparing the spatial finding with the organ's dose-volume statistic. A high-dose voxel near a boundary may also be sensitive to contour and dose-grid resolution. The dosimetrist should describe the location and uncertainty clearly for clinical review rather than deciding acceptability from one image.

Worked example: On a hypothetical axial pelvic slice, target tissue lies anterior to the rectum and posterior to the bladder. A posterior high-dose patch appears to touch the rectal contour. Follow the patch and rectum on sagittal and coronal views: if the patch continues through several superior slices inside the rectum, it represents a meaningful organ region; if it separates on adjacent slices, the first axial view overstated the overlap.

Watch the distinction: One axial slice cannot establish the full extent of a hotspot or organ overlap. Trace the finding through three planes and compare it with the correct dose metric.

Reference: [1]

21. Forward planning and beam geometry

In forward planning, you choose beam directions, field borders, and weights, then calculate and inspect the resulting dose. Start by tracing each beam through the patient: where it enters, how much target depth it must cover, where it exits, and which organs lie along that path. Opposed beams can provide coverage through a thick target, but both traverse tissue beyond the target. Tangential beams skim a superficial target and may reduce dose to deeper anatomy. Field shaping limits exposure outside the intended area, while beam overlap can create a hotspot and a poorly matched edge can create a cold region. Review isodoses on the patient images and the target and organ dose metrics together. The MDCB applicant handbook includes forward planning and beam arrangement evaluation in its scope.

Worked example: A superficial target lies on the lateral chest wall, with lung immediately deep to it. Two opposed beams would pass through the chest and create substantial deep exit dose. A tangential pair follows the chest wall more closely, so it is a reasonable starting geometry. Calculate both arrangements, then inspect the deepest target edge, field junctions, and lung dose before recommending either plan.

Watch the distinction: A tangent that appears to avoid lung on one axial slice may miss a deeper part of the target elsewhere. Check coverage and organ dose throughout the volume.

Reference: [1]

22. Inverse planning and modulation

Inverse planning begins with target and organ objectives. The optimizer varies beam fluence to reduce a mathematical penalty; the resulting intensity pattern is translated into deliverable multileaf collimator positions and monitor units. IMRT uses modulated fields, while VMAT also varies parameters during gantry rotation. A favorable objective score can conceal very small apertures, excessive leaf travel, sensitivity to motion, or steep dose changes near a moving boundary. Inspect the actual dose distribution and DVH after sequencing, since the deliverable plan can differ from the ideal fluence. Check machine limits, collision clearance, and the relevant patient-specific delivery measurements with the qualified team. The dosimetrist can revise objectives and geometry, but a plan's clinical suitability and delivery verification require the established multidisciplinary review. MDCB practice questions can help reinforce this sequence.

Worked example: An optimizer covers a moving lung target by placing many narrow MLC openings along its inferior edge. The nominal DVH meets the stated target objective, yet the target moves across those openings during delivery. Review motion-inclusive coverage, aperture size, leaf sequence, and delivery QA results. A good nominal DVH alone does not establish accurate delivered coverage.

Watch the distinction: An optimization objective describes what the software tries to improve. It is not proof that the sequenced beam is deliverable or that motion preserves the calculated dose.

Reference: [1]

23. Optimization objectives are proxies

An objective compresses part of a three-dimensional dose distribution into a number the optimizer can use. A minimum-dose objective encourages coverage, while a maximum-dose objective discourages hotspots. A volume objective asks how much structure may receive a specified dose, so its meaning depends on whether volume is reported in cubic centimeters or percent. Equivalent uniform dose summarizes a nonuniform distribution through a model whose parameter determines how strongly high or low doses influence the result. None of these numbers identifies the anatomical location of a problem. For an organ with focal injury concern, a small-volume high-dose metric can be more informative than its mean. For a broad parallel organ, mean or larger-volume exposure may also matter. Match every objective to the approved clinical aim, then inspect spatial dose and the full DVH before interpreting success.

Worked example: A hypothetical organ is 100 cm³. Its mean dose falls from 12 to 11 Gy, but its hottest 0.1 cm³ rises from 24 to 29 Gy. The lower mean satisfies a mean-dose objective more comfortably, yet it does not address a focal hotspot. Display D0.1 cm³ and locate that region on the images for clinical review.

Watch the distinction: Improving an organ's mean dose does not guarantee that every voxel improved. A small high-dose region can worsen while most of the organ receives less dose.

Reference: [1]

24. Robust and multicriteria planning

A nominal plan is calculated on one assumed patient position and anatomy. Robust evaluation asks how its target coverage and organ doses change under stated setup shifts or, for protons, range variations. Multicriteria planning explores a tradeoff surface: improving one metric may worsen another, and no single plan is automatically best on every measure. Compare plans using the same structures, prescription, dose units, and uncertainty scenarios. Record both the nominal result and the worst relevant tested outcomes, including where cold and hot regions occur. A robust plan need not have the prettiest nominal DVH. Conversely, robustness testing covers only the shifts and anatomy changes included in the test. Present the competing results to the clinical and physics reviewers so selection reflects the case's priorities and the uncertainty the team can reasonably expect.

Worked example: Suppose both plans cover 98% of a target at the prescribed dose on the planning CT. Plan A has a slightly lower nominal organ mean, but a tested 3 mm shift reduces target coverage to 90%. Plan B's coverage remains 96% under that shift. Present the organ benefit alongside these perturbed results; the nominal organ metric alone cannot rank the plans.

Watch the distinction: A robust result under tested shifts does not guarantee performance under every anatomical change. State the scenarios examined and investigate changes outside those assumptions.

Reference: [1]

25. Proton range uncertainty

Protons deposit energy as they slow, producing a distal falloff that can spare tissue beyond the target. Planning CT values are converted to estimated stopping power, then integrated along each beam path to predict where that falloff lands. Conversion uncertainty, setup error, and changing tissue composition alter the water-equivalent path length. A beam traversing air, bone, and soft tissue is therefore more sensitive to some anatomical changes than a path through stable tissue. Examine the distal edge relative to critical structures and evaluate range and setup scenarios, rather than relying solely on the nominal dose. If new imaging shows a substantial path change, reassess anatomy, contours, calculation, and clinical significance with the proton planning and physics team before continued reliance on the original plan.

Worked example: A proton field crosses a sinus that contained air on the planning CT. Later imaging shows the sinus filled with fluid. Fluid increases stopping along that path, so the protons may stop sooner and leave part of the target underdosed. Recalculate on the updated anatomy and review range scenarios and adjacent-organ dose before deciding whether adaptation is needed.

Watch the distinction: A sharp distal falloff on the original CT is not a fixed anatomical boundary. Changes in material along the beam path can move it.

Reference: [1]

26. Electron field design

Electrons have a finite useful range, making them suitable for many shallow targets, but their lateral scatter broadens field edges and complicates coverage on curved surfaces. Energy selection follows target depth and the dose required at its deepest extent. Bolus adds material before the skin, moving the depth-dose pattern toward the surface while reducing the remaining penetration in tissue. A cutout shapes the field, yet its size and position can change output and edge dose. Inspect the surface, deep edge, and lateral margins on the actual patient contour. Air gaps under bolus and oblique incidence can shift the expected distribution. A shallow appearance on one slice is insufficient when target thickness varies. Use the commissioned calculation and applicable cutout factors, then review whether the chosen setup can be reproduced.

Worked example: A skin target reaches a curved lateral edge and extends several millimeters deep. A hypothetical 5 mm bolus improves near-surface dose but also uses part of the electron range before the beam enters tissue. Recalculate with the bolus represented, inspect the deepest target and curved edge, and confirm the cutout factor for that field. Do not assume the surface gain preserves deep coverage.

Watch the distinction: Bolus does more than increase skin dose. It changes the effective depth of every point beneath it, so deep coverage must be checked again.

Reference: [1]

27. SRS and SBRT precision

SRS and SBRT deliver a high dose per fraction with a steep falloff outside a small target. A positioning error or unmodeled motion can therefore move tissue across a large dose gradient. Planning connects immobilization, image guidance, motion management, small-field beam modeling, and organ review. Determine whether the target is stationary enough for the selected delivery or whether breath hold, gating, tracking, or a motion envelope is needed. Check target coverage across relevant motion states and inspect nearby organ dose in three dimensions. Small apertures also demand attention to machine accuracy and patient-specific delivery verification. A highly conformal nominal plan is only one part of the evidence; its geometry must remain appropriate from localization through treatment.

Worked example: A lung target moves 7 mm between observed breathing extremes, while the steep-dose region spans about 7 mm. A match to one static phase could place the target near the low-dose side during another phase. Review the four-dimensional motion envelope, selected delivery strategy, target coverage, and adjacent-organ doses. Escalate any mismatch before approval.

Watch the distinction: Sharper falloff does not automatically make a stereotactic plan safer. It also makes localization and motion errors more consequential near the target boundary.

Reference: [1]

28. Large-field special procedures

Total body irradiation uses a large treatment region and often an extended treatment distance. Output, patient thickness, beam obliquity, shielding, and junctions can vary substantially across the body. A reference calibration at standard geometry cannot simply be transferred without the validated extended-distance method and measurements. In-vivo dosimetry can test whether selected locations receive the planned dose, while setup reproducibility remains important across fractions. Total skin electron irradiation or beam therapy has a different goal: broad skin coverage with limited deep penetration. Multiple patient positions and fields create overlap and underlap risks, especially at folds and junctions. For either procedure, trace what each field actually covers, identify regions that may need special attention, and use measurements and clinical review appropriate to the commissioned technique.

Worked example: A hypothetical total body setup places the patient farther from the source than the machine's reference point. The changed distance reduces fluence, while body thickness makes central and peripheral doses differ. The dosimetrist uses the commissioned extended-distance method and planned in-vivo checks. For a total skin electron case, review surface coverage and field junctions instead of treating deep midline dose as the main endpoint.

Watch the distinction: Scaling standard-distance monitor units by distance alone ignores patient thickness, beam overlap, and the validated setup. Large-field procedures require their own measured geometry.

Reference: [1]

29. When anatomy calls for adaptation

An approved plan represents the anatomy captured for its calculation. Tumor shrinkage, weight change, organ filling, or a shifted critical structure can alter coverage and organ dose even when machine parameters are unchanged. First verify that the apparent change is real and that the new images are suitable for comparison. Review registration, contours, setup, and the dose difference on corresponding anatomy. Estimate whether the original beams still cover the intended target and whether organ exposure has changed. If the difference matters, prepare an updated planning assessment for physician and physics review. A revised contour or recalculation does not itself authorize a new treatment plan. Adaptation should preserve a clear record of the original plan, accumulated treatment, revised prescription assumptions, and approvals.

Worked example: Midcourse imaging shows a smaller head-and-neck target and a parotid gland shifted toward a high-dose region. Confirm positioning and image registration, update the relevant contours for assessment, and recalculate or estimate dose on the new anatomy. Report target coverage and parotid change to the clinical and physics team before any revised plan is approved.

Watch the distinction: Tumor shrinkage does not necessarily mean the old plan is now better. Nearby organs may move into high dose, and the prescribed target may include more than visible disease.

Reference: [1]

30. Normalization and isodose meaning

An isodose percentage expresses dose relative to a defined normalization value. The reference might be the prescription dose, a selected point, or another planning convention, so read the display settings before converting a percentage to Gy. Multiplying the reference dose by the displayed fraction gives the absolute dose only under that stated convention. Then inspect the line's three-dimensional location, volume, and relationship to target and organs. A hotspot inside target tissue has a different implication from the same dose in a nearby critical structure. Normalization can move the apparent percentage labels without changing the underlying spatial pattern. Compare plans using absolute dose and consistent prescription and structure definitions, and check whether the displayed line reflects physical dose or another explicitly labeled quantity.

Worked example: A hypothetical plan is prescribed to 60 Gy, and the display defines 100% as 60 Gy. Its 110% line therefore marks 1.10 × 60 = 66 Gy. If that 66 Gy region is confined to the target, review its volume and clinical relevance. If it reaches a critical organ, inspect the organ's high-dose metric and anatomy before accepting the plan.

Watch the distinction: A 110% label does not always mean 110% of prescription. Confirm the normalization reference before converting it to Gy or comparing plans.

Reference: [1]

31. Four ways to display a DVH

A dose-volume histogram pairs dose with the amount of a structure receiving it. In a cumulative DVH, V30 means volume receiving at least 30 Gy. In a differential DVH, a bar or bin represents volume within a stated dose interval; it does not include all higher-dose voxels. Either view can show volume in cubic centimeters or as a percentage of the structure's total volume. Convert between those units using the correct structure volume. Keep the dose axis in its displayed units: the MDCB handbook describes absolute dose in Gy for its plan-review platform. A DVH loses spatial information, so locate any concerning high-dose region on axial, sagittal, and coronal images. The related radiation therapy study guide can help reinforce the underlying dose and anatomy vocabulary.

Worked example: A 100 cm³ organ has 20 cm³ receiving at least 30 Gy. Cumulative V30 is 20 cm³ on an absolute-volume plot and 20 ÷ 100 × 100 = 20% on a relative-volume plot. If the differential 30–35 Gy bin is 6 cm³, that bin contains only dose in that interval. It cannot replace cumulative V30.

Watch the distinction: A differential bin at 30 Gy is not V30. Check the dose interval, cumulative setting, and whether volume is shown in cm³ or percent.

Reference: [1]; [2]

32. Apply the right organ constraint

An organ constraint is meaningful only with its complete definition: the named structure, dose statistic, volume unit, fractionation, and dose basis. D0.1 cm³ commonly denotes the dose to the hottest 0.1 cm³, while D1 cm³ summarizes a larger hot volume. The smaller-volume value can be higher, so a reassuring D1 cm³ cannot establish compliance with a D0.1 cm³ limit. Likewise, a whole-organ mean cannot substitute for a substructure maximum. Confirm whether the reference uses physical Gy or a specified biological conversion, and whether prior treatment must be considered. Check that the reported structure matches the protocol's contour definition. Retrieve the exact metric from the correct approved dose and use the result as part of clinical review, with spatial inspection of any hotspot.

Worked example: A hypothetical protocol specifies D0.1 cm³ ≤ 25 Gy for a defined organ. The plan report lists D1 cm³ = 24 Gy. That larger-volume statistic does not answer the question; the hottest 0.1 cm³ might receive 27 Gy. Generate D0.1 cm³ in Gy for the specified structure and fractionation, locate the hotspot, and report the actual comparison.

Watch the distinction: A dose metric with a similar name is not interchangeable. Changing the hot-volume size, structure, or fractionation can reverse the interpretation.

Reference: [1]

33. Implants and devices in the beam path

Implants and wearable devices can affect imaging, dose calculation, beam access, or treatment coordination in different ways. A dense prosthesis may create CT artifacts and a high-attenuation beam path. A fiducial can help localization but may obscure a small area on images. A spacer changes the anatomy between target and organ, while a pacemaker or glucose monitor raises device-specific placement and clinical coordination questions. Identify each device on simulation images and in the chart, then determine which beam paths or contours it affects. Corrupted CT numbers cannot be assumed to represent actual tissue density. Where a density override is justified, define its extent, rationale, and uncertainty with physics input, recalculate affected fields, and inspect alternate geometry. The dosimetrist brings planning consequences to the team without independently deciding device management.

Worked example: A hip prosthesis causes bright and dark streaks through soft tissue beside a pelvic target. Mark the voxels whose density is unreliable, inspect whether planned beams cross the prosthesis, and compare a documented physics-reviewed override with the original calculation. If an alternate beam path avoids the artifact without sacrificing coverage, present that option alongside the recalculated dose.

Watch the distinction: A CT streak is an image artifact, not a measured tissue property. Assigning its displayed density directly to dose calculation can create false attenuation.

Reference: [1]

34. Choose a delivery system for the case

Technique choice begins with the target's depth, shape, motion, and relationship to nearby organs. Conformal photons are relatively straightforward when a few shaped beams can cover the target. Modulated photons can improve shaping around irregular anatomy, but may increase the amount of tissue receiving low dose and require careful delivery verification. Electrons suit shallow regions when their finite range and lateral scatter can still cover the full target. Protons may reduce exit dose, provided range and anatomy uncertainty are acceptable. Compare options on the same prescription, anatomy, target coverage, organ metrics, and likely setup variation. Consider access for imaging, immobilization, collision clearance, and reproducible bolus or apertures. A technology label alone cannot establish the best plan; the candidate should explain the physical tradeoffs and prepare a defensible comparison for clinical selection.

Worked example: A shallow irregular target wraps around a deep organ. Electrons might spare depth but struggle where target thickness varies. Photons can shape coverage but may deliver exit dose through the organ. Protons could reduce exit dose, yet their distal edge would depend on tissue along the path. Calculate viable geometries and compare coverage, organ dose, motion, and range sensitivity.

Watch the distinction: Choosing the modality with the least apparent exit dose can miss a coverage or uncertainty problem. Compare complete plans under the case's actual geometry.

Reference: [1]

35. Control plan and image versions

A treatment plan is a connected set of records, not an isolated dose image. The planning CT, structure set, dose object, beam plan, prescription, approvals, and exported treatment record must refer to the intended patient, course, and image series. DICOM identifiers and references help reveal when a revised scan or contour was imported but an older plan remained active. Scripts and templates can repeat a version error rapidly, so inspect their inputs and outputs. Archive approved versions and preserve enough information to reconstruct what was reviewed; backups protect availability but do not establish which version was approved. Before transfer or release, trace the plan's image and structure references, dose calculation, and approvals through the receiving system. The healthcare quality guide provides related context for process controls and error prevention.

Worked example: A revised planning CT is imported after optimization, but the exported plan still references the original CT series UID. Its dose display may look plausible while representing old anatomy. Stop the transfer, identify the CT and structure set used by the beam and dose objects, then recalculate or verify the intended version and obtain the required reviews before release.

Watch the distinction: A correct plan name does not prove correct image association. Inspect linked identifiers and approved records, especially after imports, replanning, or scripted exports.

Reference: [1]

36. Validate automated planning outputs

Automation can accelerate contouring, objective setup, and plan creation, but its output inherits errors from images, templates, structure names, and training assumptions. Auto-contours may omit an organ tip, cross a boundary, or include an adjacent structure. A generated DVH can then look favorable simply because the measured organ volume is incomplete. Inspect contours on axial, sagittal, and coronal views, including first and last slices and regions close to steep gradients. Verify that scripts selected the intended patient, image, prescription, and structure names. After corrections, recalculate dose metrics and review spatial dose rather than relying on the earlier optimization score. Record what changed and route the corrected plan through normal approvals. Human review is most valuable at interfaces where a plausible automated result could hide a consequential anatomical or data-link error.

Worked example: An auto-contour misses the superior tip of an organ on three slices next to a high-dose field. Its reported D0.1 cm³ is low because the omitted tissue is absent from the DVH. Correct the existing contour in all three planes, recalculate the plan statistics, and document whether the recovered tissue changes the organ assessment before accepting the plan.

Watch the distinction: A favorable DVH does not validate the contour used to create it. Missing anatomy can make a real hotspot disappear from the report.

Reference: [1]

Dose Calculation Methods

37. Select and question a dose algorithm

Dose algorithms differ in how they represent primary photons, scattered radiation, and secondary charged particles. A simple correction-based method adjusts for density along a ray but may poorly capture lateral electron transport near a small field or tissue interface. Convolution and superposition methods spread energy using modeled kernels and heterogeneity information. Monte Carlo simulates particle histories and can represent complex transport in detail, though its results depend on the beam model, material assignment, and statistical precision. No algorithm repairs a wrong contour or corrupted CT density. For a field crossing lung, inspect dose near the lung-target interface and compare the approved method with commissioning measurements or an independently validated calculation where appropriate. Select the method according to the site's commissioned use and the geometry's sensitivity.

Worked example: A narrow photon beam traverses low-density lung before a small target. A ray-based density correction predicts target dose from attenuation but may miss electrons escaping laterally from the narrow field. Recalculate with the commissioned heterogeneity-aware method, compare interface coverage and measured or validated expectations, and investigate any clinically relevant difference before relying on the plan.

Watch the distinction: A more detailed algorithm is not automatically accurate for every case. Its beam model, CT material mapping, grid, and commissioning range still matter.

Reference: [1]

38. Modifiers change fluence and buildup

Beam modifiers alter different parts of the dose process. Bolus adds material before the skin and moves buildup toward the surface. A wedge creates a fluence gradient across the field; a compensator varies attenuation to address patient shape or a desired intensity pattern. MLC leaves define apertures or modulate fluence, while a partially transmitting block attenuates rather than completely removes part of a beam. Each modifier can change output, scatter, penumbra, and dose beyond the intended region. Identify the physical problem first: shallow underdose, lateral gradient, irregular boundary, or partial shielding. Then select a supported device and recalculate on the patient's geometry. Check its orientation, thickness or transmission, field position, and deliverability. A single uniform correction factor rarely describes the full three-dimensional change.

Worked example: A hypothetical field is too hot on one lateral side and underdoses tissue near the skin. A wedge can tilt the lateral dose distribution; 1 cm bolus moves buildup toward the surface. They address different problems. Model both in the treatment geometry, verify wedge orientation and bolus fit, and recalculate target and organ dose instead of multiplying the original plan by one factor.

Watch the distinction: Bolus and a wedge are not interchangeable dose reducers. Bolus changes effective depth; a wedge changes fluence across the field.

Reference: [1]

39. Reference output and monitor units

A monitor-unit calculation relates the requested dose at a specified point to calibrated output and all relevant correction factors. In a simplified model, dose in cGy equals MU times reference output in cGy/MU times dimensionless factors for field, depth, and other stated conditions. Rearranging gives MU = requested cGy divided by the product of cGy/MU and those factors; the units reduce to MU. Define the beam energy, geometry, calculation point, and whether each factor is already included before multiplying. If the prescription is to a volume rather than the calculation point, a separate plan evaluation establishes coverage. Independently check arithmetic and compare the result with the treatment planning system and commissioned expectations. The formula is useful for reasoning, but its numerical factors must come from the applicable measured model.

Worked example: A hypothetical photon beam delivers 1 cGy/MU at reference conditions. Its combined field and depth factor at the chosen point is 0.80, so output there is 0.80 cGy/MU. To deliver 200 cGy at that point, MU = 200 cGy ÷ 0.80 cGy/MU = 250 MU. This applies only to the stated beam, point, and factor assumptions.

Watch the distinction: Dividing by a factor without checking what it already contains can double-correct output. Write the dose equation and units before inserting numbers.

Reference: [1]

40. Off-axis and junction calculations

A beam profile describes how dose changes away from central axis under defined depth, field, and geometry conditions. An off-axis factor is the dose at a selected point divided by central-axis dose under otherwise matching conditions. It can estimate that point's dose when the reference geometry truly matches, but it does not describe the sum of two neighboring fields. At a junction, penumbrae from adjacent fields may overlap to create excess dose or separate to create a cold strip. Divergence, patient contour, depth, setup variation, and shifts between fractions affect the junction. Inspect composite dose on images and calculate or measure the junction with the commissioned method. When a field match is intentionally varied, evaluate the cumulative pattern rather than a single-fraction line. Keep point calculations tied to their depth and coordinate definitions.

Worked example: A hypothetical central-axis calculation gives 200 cGy at the target depth, and the matched profile gives an off-axis factor of 0.90 at a target point. Its estimated dose is 200 × 0.90 = 180 cGy under the same conditions. If that point lies near an adjacent-field junction, calculate the composite dose there; the neighboring field may add dose or leave an underlap.

Watch the distinction: An off-axis factor from one field is not a junction factor. Junction dose depends on both fields' edges, divergence, depth, and setup.

Reference: [1]

41. Density overrides and missing tissue

CT numbers help a treatment planning system estimate how radiation travels through tissue. Metal streaks, motion, truncated anatomy, and contrast can make those numbers poor representations of the material actually in a beam path. First identify which voxels are suspect and whether the affected region lies under a treatment beam. Compare the scan with reliable imaging and the visible anatomy, then determine whether a supported material or density override is appropriate. An override changes the calculation input; it does not repair the image or reveal the true density. Recalculate, inspect dose changes along every affected path, and have the assumption reviewed by physics before relying on the result. If part of the patient is absent from the scan, a density override cannot reconstruct the missing external contour or beam attenuation. Adequate imaging may be needed.

Worked example: A pelvic CT assigns a metal-streak region within visible soft tissue an implausibly high density. A validated comparison image supports identifying the region as soft tissue, and physics reviews a proposed override. The dosimetrist calculates the plan with and without it, then compares target and organ dose along beams crossing the streak. The difference shows sensitivity to the assumption, not the exact dose the patient will receive.

Watch the distinction: Treating a corrected-looking dose distribution as proof that the assigned density is exact overlooks uncertainty in the image, material assignment, and beam model.

Reference: [1]

42. Entrance, exit, and prior-course dose

An entrance or exit dose check asks what reaches a defined surface or measurement point under a stated beam geometry. It can expose a setup, field, or calculation discrepancy, but the point and its uncertainty must be identified before comparing it with a plan. Prior-course review is a spatial problem as well as arithmetic. Confirm that both doses use compatible units, refer to corresponding anatomy, and have an understood registration between image sets. Physical absorbed doses in Gy can be added at a mapped location, while biological interpretation also depends on dose per fraction, elapsed time, tissue response, and the reliability of the mapping. A dosimetrist can prepare and scrutinize a composite calculation; clinical acceptance of a retreatment plan requires the appropriate physician and physics review.

Worked example: A mapped region receives 18 Gy physical dose in an earlier course and 12 Gy in a proposed course. Assuming the registrations identify the same tissue and the values represent compatible absorbed dose, the arithmetic sum is 18 + 12 = 30 Gy. That is a physical-dose total. Different fraction sizes or uncertain correspondence could change its clinical interpretation, so the dosimetrist presents those limits with the composite.

Watch the distinction: Adding two plan labels or organ maxima does not establish the dose to the same tissue. The locations, units, fractionation, and registration must be checked first.

Reference: [1]

43. Deformable dose accumulation

A plan summary compresses a three-dimensional dose distribution into a few statistics. Deformable accumulation instead attempts to map dose from changing anatomy onto a chosen reference image and add corresponding spatial values. That process depends on whether the registration truly follows the relevant tissue, particularly near sliding surfaces, surgery, shrinking tumors, or organs that fill and empty. Inspect the deformation, contours, and mapped hot regions in multiple planes before trusting a composite DVH. The selected reference anatomy and mapping direction can affect the result. For nonnegative dose fields mapped to corresponding points, the sum of separate organ maxima bounds the composite maximum from above, but usually overstates it when the maxima occur in different places. A technically plausible map still carries uncertainty that belongs in the reported interpretation.

Worked example: One course has an organ maximum of 20 Gy and another has 15 Gy. Their sum, 35 Gy, is an upper bound on the mapped pointwise maximum if both fields cover corresponding tissue and contain nonnegative doses. It is not a measured composite maximum. The dosimetrist maps both distributions to a reference anatomy, checks the registration near each hotspot, and reads the resulting spatial dose and DVH.

Watch the distinction: A deformable registration can produce a smooth-looking composite even when it maps one organ surface to the wrong tissue. Visual continuity alone is insufficient validation.

Reference: [1]

44. Calculation resolution and uncertainty

A calculated dose is sampled on a grid, so features smaller than its spacing may be blurred, shifted, or missed. Contour voxel size adds another limit: a small structure may change volume substantially when its boundary moves by one image pixel. Algorithm assumptions matter too, especially near air, bone, interfaces, and small fields where charged-particle transport is difficult to model. When a small-volume maximum or steep gradient drives a decision, examine the dose on images rather than relying on a single statistic. Recalculate at a supported finer resolution and compare the result, while keeping the same beam and model assumptions. A finer grid can reduce sampling error, but cannot correct an unsuitable algorithm, inaccurate contour, or uncertain machine data. Report the metric with enough context to show which limitation remains.

Worked example: A hypothetical hotspot is 3 mm wide, while the calculated dose grid is spaced 5 mm apart. Because 3 mm is less than 5 mm, a sample point may fall outside the peak or place it in a neighboring voxel. The dosimetrist uses an appropriately supported finer grid, compares dose profiles and anatomy, and checks the small-volume metric again before interpreting its location.

Watch the distinction: Increasing display zoom does not increase calculation resolution. A sharply rendered color wash may still come from a coarse sampled dose grid.

Reference: [1]

Brachytherapy

45. Brachytherapy source strength and time

Brachytherapy dose depends on source strength, dwell duration, and the location and orientation of the source relative to tissue. Radioactive decay reduces strength with time according to the isotope's physical half-life. For an otherwise identical geometry and source model, dose is approximately proportional to strength multiplied by dwell time, so less strength calls for more time to reach the same modeled dose. Distance changes the local dose steeply, while source anisotropy, applicator material, and shielding can disturb a simple point-source estimate. Keep activity or calibrated source strength separate from dose rate, delivered dose, and elapsed treatment time; they have different units and meanings. Use the current calibrated strength and verified source position in the plan rather than transferring dwell times from an earlier source without recalculation.

Worked example: A hypothetical HDR source falls from strength S to S/2 after one physical half-life. If a dwell originally lasts 20 seconds and all geometry and modeling assumptions remain identical, maintaining its modeled contribution requires 20 × 2 = 40 seconds. That idealized calculation does not approve the treatment: the calibrated strength, applicator geometry, dwell positions, and full plan still need verification.

Watch the distinction: Doubling dwell time cannot compensate for a displaced applicator. The source may then irradiate different tissue even if its total emission over time is similar.

Reference: [1]

46. Applicator geometry drives dose

Intracavitary applicators place source paths within a body cavity; interstitial needles or catheters place them through tissue. Either arrangement makes geometry central because tissue close to a source sees a steep dose change with distance. HDR generally uses a temporarily driven source with planned dwell positions and times, whereas LDR arrangements deliver over a longer period using their own source and placement methods. A plan therefore depends on the reconstructed applicator and current patient anatomy, not merely the applicator name. Check channel identity, source path, orientation, and the relationship of target and nearby organs before interpreting a DVH. If an applicator moves, assess the new geometry and recalculate rather than assuming that a prior dwell pattern remains valid. Escalate reconstruction uncertainty before release.

Worked example: A vaginal cylinder shifts relative to the target after the planning image. The dosimetrist compares its current position and channel path with the original reconstruction, then recalculates target coverage and adjacent-organ dose on the new geometry. Even if the dwell times are unchanged, the nearest tissue has moved relative to the source, so the earlier dose distribution no longer describes the case reliably.

Watch the distinction: A correct applicator model does not guarantee a correct plan when its position has changed. Source-to-tissue distance and channel reconstruction must match the current setup.

Reference: [1]

47. Brachytherapy surveys and handoffs

Brachytherapy handoffs must account for the physical source as well as the electronic treatment record. Inventory and source identity establish what is available; reconstruction and plan checks establish where it is intended to deliver dose. Background and treatment-area surveys provide independent evidence about the radiation field before and after a procedure. A post-treatment survey that differs unexpectedly from established background warrants source-location investigation, even when the console reports completion. Limit access, maintain shielding and controlled-area precautions, and involve the qualified radiation-safety and physics team. The dosimetrist supports accurate source, plan, and record reconciliation within the team rather than independently declaring the area safe. Regulatory responsibility depends on applicable NRC or state requirements and the facility's authorized program; the MDCB applicant handbook identifies these topics in the CMD scope.

Worked example: After a temporary implant, a survey at the patient location is above the measured preprocedure background. The team keeps access controlled and follows the source-location response while checking the instrument, survey position, inventory, and treatment record. A normal console completion message cannot resolve the physical reading. Qualified radiation-safety personnel determine the next survey and release steps under the applicable program.

Watch the distinction: Closing the chart because planned dwell positions were completed confuses delivery records with evidence that the source has returned and the area is clear.

Reference: [1]

Radiation Protection

48. Apply time, distance, and shielding

ALARA guides practical reduction of unnecessary radiation exposure through shorter time, greater distance, and suitable shielding. For a stationary ideal point source, dose rate varies approximately as the inverse square of distance; total exposure then scales with time at that rate. The model is useful for estimating the direction and size of a change, but an extended source, walls, scatter, and changing positions can alter the measured field. Shielding depends on radiation type, energy, thickness, and geometry. Start by asking whether an unexpected source or field needs control; routine optimization does not replace that response. For a planned task, identify the needed work, estimate where staff will stand, use an appropriate barrier, and verify actual conditions with a suitable instrument when required.

Worked example: Suppose an ideal point source gives a worker a modeled exposure E during a task lasting time t at distance r. Moving to 2r changes dose rate to E/4 for the same time. Completing the task in t/2 makes exposure E/4 × 1/2 = E/8. This estimate assumes fixed geometry and ignores scatter or shielding changes.

Watch the distinction: The inverse-square rule does not justify approaching an unidentified source. Control and measurement come before optimizing work around an abnormal field.

Reference: [1]

49. Monitor distinct exposure groups

Occupational, public, and patient exposures are monitored for different decisions. A worker's personal dosimeter estimates accumulated exposure associated with work; an area survey characterizes a location; a patient's treatment record documents intended and delivered therapeutic dose to specified anatomy. These are not interchangeable records or necessarily the same dose quantity. A declared-pregnancy context can change how occupational exposure is assessed and documented under the applicable monitoring program, while patient pregnancy questions require clinical assessment of the proposed treatment. The dosimetrist should identify which person, period, quantity, and source of exposure a number describes before interpreting it. Comparing a badge reading directly with a prescribed organ dose mixes purposes and units. Related radiation therapy study material can reinforce detector and treatment-dose terminology, while the CMD task requires connecting those measurements to planning and team review.

Worked example: A therapist's badge reports an accumulated occupational reading, while a patient's chart records 2 Gy absorbed dose prescribed for a treatment fraction. The badge describes the worker's exposure over its monitoring period; 2 Gy describes energy deposited per unit mass in planned patient tissue. Neither number can be substituted for the other. A pregnancy-related worker review follows the relevant monitoring and regulatory program.

Watch the distinction: A patient's therapeutic Gy value is not an occupational badge result. The measured person, dose quantity, anatomy, and time period determine its meaning.

Reference: [1]

50. Primary and secondary vault barriers

A primary barrier is designed for directions in which the useful treatment beam can strike it directly. Secondary barriers address radiation that reaches other surfaces through head leakage and scatter from the patient or room. That distinction follows allowed machine orientations and beam geometry, not whether a wall seems close to the treatment couch. Formal vault analysis also considers workload, how often the beam points toward each barrier, occupancy beyond it, beam energy, and the relevant design criteria. A door or maze may require its own assessment because scattered radiation can follow paths unlike the direct beam. The dosimetrist should recognize whether a proposed technique changes the directions or workload assumed for a room and raise that question for shielding specialists. Barrier thickness cannot be inferred from a simple room sketch.

Worked example: In a stated vault layout, a treatment beam can point directly toward the west wall but never toward the corridor wall. The west wall requires primary-beam analysis; the corridor wall is assessed for leakage and scatter as a secondary barrier. A formal design then applies the actual workload, direction use, occupancy, energy, and geometry rather than assigning thickness from these labels alone.

Watch the distinction: Calling every wall a primary barrier ignores whether the useful beam can hit it. Calling an unstruck wall harmless ignores leakage and scatter.

Reference: [1]

51. Match detector to measurement

Choose a detector by the quantity, radiation field, and time scale to be measured. A calibrated ion chamber can support reference beam output measurements when used with its appropriate calibration and correction procedure. A diode is small and responsive, useful for suitable relative measurements or defined patient checks, but its energy, angle, and dose-rate behavior must be understood. A survey meter investigates radiation fields in accessible locations within its specified range and radiation response. A passive personnel dosimeter integrates exposure over a wear period and does not give an immediate location reading. Thermoluminescent or similar passive devices can also serve defined measurement tasks with calibration. Before acting on a result, check instrument identity, calibration status, background, geometry, and whether the reading's units answer the question being asked.

Worked example: A team needs reference linac output, a reading near a completed source procedure, and a worker's accumulated exposure. They select a calibrated reference ion chamber for output, a suitable survey meter for the accessible field, and the worker's assigned passive badge for the monitoring period. A fast diode may aid a defined beam check, but speed alone does not qualify it for reference calibration.

Watch the distinction: A detector that responds to radiation is not automatically suitable for every measurement. Calibration range, energy response, geometry, and intended quantity matter.

Reference: [1]

52. Respond to an abnormal radiation reading

An unexpected radiation reading is first a control and verification problem. Restrict unnecessary access and avoid moving people closer merely to repeat the measurement. Record where, when, and with which instrument the reading occurred; compare it with an established background and check range, battery or status indications, and the instrument's suitability. Repeat from a safe location or have qualified personnel confirm it using the facility response process. Consider a retained source, a contaminated or misplaced item where relevant, instrument error, and scatter from another activity without choosing one explanation prematurely. Notify radiation safety and physics promptly, preserve the survey and treatment records, and let the responsible team determine source location and release. A normal electronic treatment status cannot overrule a credible physical measurement.

Worked example: A survey meter reads above established background near a patient after a source procedure. Staff limit access and document the location, time, instrument, and reading. From a safe position, qualified personnel verify instrument function and repeat or cross-check the survey, then investigate source inventory and location. The dosimetrist supplies plan and source records while the radiation-safety team directs clearance.

Watch the distinction: Dismissal because the console shows treatment complete skips independent evidence. An abnormal survey must be reconciled with the physical source and instrument.

Reference: [1]

Quality Assurance & Standard of Care

53. Commissioning versus routine QA

Commissioning establishes the data and validated model needed to use a treatment machine or beam clinically. It includes characterizing output, depth dose, profiles, field-size behavior, and other features relevant to the intended techniques, then testing whether calculations agree with appropriate measurements. Routine quality assurance compares a commissioned system against its baseline to detect drift or faults over time. A passing daily check shows that the tested parameter remains within its defined program criteria; it does not create missing model data for a new energy or technique. Likewise, a model can be properly commissioned yet later fail a routine check. The dosimetrist should confirm that the selected energy, accessories, field sizes, and delivery method lie within the validated clinical configuration before planning or release, and refer unsupported conditions for physics assessment.

Worked example: A new beam energy appears in the planning system, but depth-dose, profile, and output data have not been commissioned. A daily output check on an existing energy passes. That result says nothing sufficient about the new energy's dose model. The plan is held until appropriate beam characterization, model validation, and clinical authorization are completed.

Watch the distinction: A routine QA pass is evidence about a tested baseline, not permission to use a different uncommissioned beam model or accessory.

Reference: [1]

54. Check the plan as a connected record

A treatment plan is a connected clinical record: prescription, patient and course identifiers, planning images, structures, beams, calculated dose, setup instructions, approvals, and transferred treatment parameters must refer to the same intended case. A plausible dose distribution does not prove that the correct image or prescription was used. Check laterality and orientation directly on the image, then trace image-series and structure-set associations to the plan and approval record. Reconcile prescription dose and fractionation with the plan's displayed units and schedule. Inspect unusual differences between simulation notes, chart text, and machine parameters before handoff. When a mismatch appears, preserve the conflicting records and stop release until the appropriate team resolves which source is authoritative. MDCB practice questions can be used to rehearse this record-tracing decision sequence.

Worked example: The prescription and plan name say left pelvis, but the image set associated with the approved plan shows a right-sided setup. The dosimetrist checks patient and course IDs, image-series identifiers, orientation, structure-set association, and approval history. Because a name alone cannot resolve the conflict, the handoff stops while the team establishes the intended images and regenerates or reapproves affected records.

Watch the distinction: Matching plan and prescription names does not prove the plan uses the intended images. Data associations and anatomy can expose a version or laterality error.

Reference: [1]

55. Measure what delivery can reproduce

A calculated beam must be reproducible by the treatment unit and its accessories. Electron cutout shape and field size can alter output and scatter, so a factor measured for another cutout may give the wrong dose. Modulated photon plans introduce small apertures, leaf motion, and control-point sequencing that require appropriate model validation and delivery QA. Measurement equipment must suit the field and quantity being checked; an ion chamber, diode, film, or array can each answer different questions under validated conditions. Review machine limits such as leaf travel, jaw positions, gantry clearance, and minimum deliverable apertures alongside the DVH. If a required factor or delivery check is missing, obtain the commissioned measurement or qualified physics assessment, recalculate the plan, and reassess coverage and organ dose before approval.

Worked example: An electron plan uses a patient-specific cutout, but its calculation uses an output factor from a different field size. Physics supplies or measures the factor for the actual energy, applicator, cutout, and setup. The dosimetrist updates the calculation and compares target and organ doses with the prescription. A previously favorable DVH cannot validate the incorrect factor.

Watch the distinction: A plan that looks conformal on screen may still be undeliverable or incorrectly normalized. Accessory factors and machine motion require independent checks.

Reference: [1]

56. Record and verify is a final defense

The oncology record and verify system connects approved plan parameters with the treatment unit and records what was delivered. It can check transferred settings against expected fields and prevent some mismatches, but it cannot determine whether a free-text instruction describes the correct patient position or whether the approved image is clinically appropriate. Review transferred beam IDs, fraction schedule, reference points, accessories, setup notes, and imaging instructions against the approved plan and simulation record. A successful import means the data were accepted electronically; it does not prove their clinical meaning. If an instruction is outdated, correct it through the established approval path and verify that the treatment record reflects the corrected version before delivery. Manual review remains especially important at interfaces between planning, charting, and the machine.

Worked example: A transferred plan has the approved dose distribution and beam parameters, but its setup note refers to an old immobilization device. The dosimetrist compares the note with simulation images and the approved chart, flags the discrepancy, and helps route the corrected instruction for review. Treatment proceeds only when the record and actual setup can be reconciled.

Watch the distinction: Electronic transfer success confirms data movement, not clinical correctness. An outdated setup instruction can persist alongside an otherwise correct beam file.

Reference: [1]

57. Escalate and learn from discrepancies

A near miss is useful safety information because it reveals a path by which an error could have reached treatment. First contain the immediate risk: identify affected plans, prevent release, preserve the original calculation and audit trail, and correct the specific error with appropriate review. Then report it through the local incident-learning process so the team can examine how it was introduced, why earlier checks missed it, and whether related cases are exposed. Root-cause analysis looks beyond the person who last touched the plan to interfaces, defaults, handoffs, and verification design. Corrective action should have an owner and a way to confirm that it works. The dosimetrist documents findings and participates within the AAMD-informed professional scope; physician, physics, and radiation-safety decisions remain with their qualified roles.

Worked example: A wrong soft-tissue density override is found before the first fraction. The dosimetrist holds the plan, preserves its previous version, obtains review of the corrected assignment, and recalculates target and organ dose. The near miss is reported. The team traces the override's origin and checks whether the same template or import step affected other plans.

Watch the distinction: Fixing only the current plan removes its immediate error but leaves the process that created or failed to catch the error intact.

Reference: [1]

Treatment Planning: contouring and plan-evaluation workflow

58. Edit a supplied contour safely

Contouring an existing structure begins by confirming the correct patient, image set, and named structure. Adjust window and level so the relevant boundary is visible, then inspect axial slices together with sagittal and coronal views. Follow anatomy and slice-to-slice continuity rather than trusting interpolation where an organ changes shape or meets neighboring bowel. Edit the supplied structure only; creating a new structure can leave the requested one unchanged. Review additions and erasures at the top, middle, and bottom of the edited span, including any holes or separate components. A text description cannot establish an image-perfect boundary, so an uncertain interface should be flagged for qualified review. Confirm the structure identity and final geometry before committing the edit. The MDCB applicant handbook describes contouring and plan-evaluation skills assessed in performance items.

Worked example: Across five pelvic slices, the supplied rectum contour follows the visible outer boundary on slices one, two, four, and five but spills into adjacent bowel on slice three. The dosimetrist edits that middle slice, checks the boundary and superior-inferior continuity in sagittal and coronal views, and verifies the rectum structure was changed. Any uncertain interface is reviewed before the edit is committed.

Watch the distinction: Accepting interpolation because neighboring slices look correct can preserve a middle-slice spill. Creating another structure also fails to correct the supplied contour.

Reference: [1]; [2]

59. Interrogate a plan and its DVH

A DVH must be read with both axes and the selected structure in view. A cumulative DVH reports the volume receiving at least each dose; a differential DVH reports volume within dose intervals. Either volume axis may be absolute, such as cm³, or relative, as a percentage of the structure's total volume. Keep the dose axis in its displayed absolute Gy and confirm that the selected dose set is the intended plan. A statistic can hide where exposure occurs, so show the relevant isodose and structure together on axial, sagittal, and coronal images. Check whether a hotspot sits inside the intended target, at an organ boundary, or in an area affected by contour or registration uncertainty. Convert between cm³ and percent only after verifying the structure volume.

Worked example: A hypothetical organ has volume 50 cm³. Its cumulative absolute DVH gives V20 Gy = 10 cm³, so the relative V20 Gy is 10 ÷ 50 × 100 = 20%. A differential bin from 20 to 25 Gy contains 4 cm³; it is not V20. The dosimetrist displays the 20 Gy isodose with the organ in three planes to locate the exposed region.

Watch the distinction: Reading a differential bin as the cumulative V20 underreports volume receiving at least 20 Gy. Check view type and volume units before interpreting.

Reference: [1]; [2]

60. Integrate geometry, coverage, and escalation

Plan evaluation joins numerical coverage with anatomy, beam arrangement, and confidence in the underlying images. Confirm prescription and target definition, then read coverage from the correct dose set and cumulative DVH with dose displayed in Gy. Compare organ metrics using the correct structures and volume units, and locate steep gradients or hotspots in axial, sagittal, and coronal views. Trace beam entry and exit paths to understand how the distribution arose. Similar target coverage does not make two plans equivalent when dose falls in different tissues. Registration uncertainty near a critical organ can undermine an apparently precise statistic; assess the fusion and contours before relying on it. The dosimetrist presents the observed tradeoff and uncertainty for physician and physics review, without independently declaring clinical acceptability or committing an unresolved plan.

Worked example: Two hypothetical plans each cover 95% of a target with at least the prescribed 60 Gy. Plan A's 66 Gy hotspot lies inside the target. Plan B's 66 Gy region overlaps 0.2 cm³ of a nearby organ where registration is uncertain. The dosimetrist checks the organ's cumulative absolute-dose DVH, inspects the region in three planes, reviews beam geometry, and escalates Plan B before final commitment.

Watch the distinction: Equal target coverage is not equal plan quality. A hotspot's anatomy and uncertain registration can change the decision even when its Gy value matches.

Reference: [1]; [2]

Official references and further reading

All study guides

Radiation Physics

1. What changes in radioactive decay

2. Activity across half-lives

3. How clinical X-rays are produced

4. Photon interactions in tissue

5. Photon, electron, and proton depth dose

6. What each treatment system delivers

7. Projection geometry and inverse square

8. Imaging signals and CT calibration

9. Radiation quantities and attenuation

Localization

10. Validate the simulation data set

11. Position for repeatability

12. Represent motion, not one snapshot

13. Check simulation completeness

14. Register images and localize treatment

Treatment Planning

15. Clinical pathways shape target review

16. From visible disease to planning volume

17. Site anatomy changes beam tradeoffs

18. Fraction size and biological effect

19. LET and RBE in interpretation

20. Read cross-sectional anatomy before dose

21. Forward planning and beam geometry

22. Inverse planning and modulation

23. Optimization objectives are proxies

24. Robust and multicriteria planning

25. Proton range uncertainty

26. Electron field design

27. SRS and SBRT precision

28. Large-field special procedures

29. When anatomy calls for adaptation

30. Normalization and isodose meaning

31. Four ways to display a DVH

32. Apply the right organ constraint

33. Implants and devices in the beam path

34. Choose a delivery system for the case

35. Control plan and image versions

36. Validate automated planning outputs

Dose Calculation Methods

37. Select and question a dose algorithm

38. Modifiers change fluence and buildup

39. Reference output and monitor units

40. Off-axis and junction calculations

41. Density overrides and missing tissue

42. Entrance, exit, and prior-course dose

43. Deformable dose accumulation

44. Calculation resolution and uncertainty

Brachytherapy

45. Brachytherapy source strength and time

46. Applicator geometry drives dose

47. Brachytherapy surveys and handoffs

Radiation Protection

48. Apply time, distance, and shielding

49. Monitor distinct exposure groups

50. Primary and secondary vault barriers

51. Match detector to measurement

52. Respond to an abnormal radiation reading

Quality Assurance & Standard of Care

53. Commissioning versus routine QA

54. Check the plan as a connected record

55. Measure what delivery can reproduce

56. Record and verify is a final defense

57. Escalate and learn from discrepancies

Treatment Planning: contouring and plan-evaluation workflow

58. Edit a supplied contour safely

59. Interrogate a plan and its DVH

60. Integrate geometry, coverage, and escalation

Official references and further reading

Frequently Asked Questions

Related Study Guides

Certified Pediatric Nurse Practitioner - Acute Care (CPNP-AC)

Psychiatric-Mental Health Nurse Practitioner (PMHNP-BC)

Certified Pediatric Nurse Practitioner - Primary Care (CPNP-PC)